Adaptive Biotechnologies Corporation (ADPT) stock analysis
Healthcare · Diagnostics & Research
From the 10-K filed 2026-02-26
Business type: Asset play
How it makes money
It generates $212.3 million from MRD testing by delivering 105,587 clonoSEQ tests to clinicians and biopharmaceutical partners.
The MRD business relies on clonoSEQ, the only FDA-authorized next-generation sequencing assay for multiple myeloma, ALL, and CLL. Profitability is driven by test volume, which grew 39% to 105,587 tests, and Medicare episode pricing for longitudinal monitoring.
It also licenses a database of 5,000,000 TCR-antigen matches to partners like Pfizer for drug discovery. It expects Immune Medicine revenue to decrease following the termination of the Genentech Agreement, which ends its eligibility for future milestone payments or tiered royalties.
What protects it: the moat
It holds FDA authorization for MM, ALL, and CLL monitoring and maintains reimbursement coverage for over 300 million lives.
Management claims its 1-in-1,000,000 cell sensitivity is uniquely suited for lymphoid cancers, positioning it as the standard choice for hematologists.
It maintains competitive distance through 416 issued patents and deep software integration into electronic medical record systems at 173 sites, creating high switching costs for oncology workflows. clonoSEQ is now used by all 33 NCCN cancer centers for longitudinal patient monitoring.
What growth costs
It used $46.0 million in cash for operations while investing in revenue cycle management for reimbursement appeals.
The company must invest in laboratory scaling and software automation to improve sample throughput and reduce costs per sample.
To fund these operations, it entered a purchase agreement with OrbiMed for $124.4 million, which granted the lender a security interest in its core platform technology assets. It continues to allocate capital to clinical evidence generation to support adoption in new indications like Non-Hodgkin Lymphoma.
What could damage it
Commercial payors can retroactively review previously paid claims and deduct determined overpayments from current amounts owed without a dispute mechanism.
Payors may perform audits of historically paid claims and recoup funds years after distribution if they determine tests were medically unnecessary.
Because it has no mechanism to dispute these retroactive adjustments, payors typically offset the determined overpayment against whatever amounts they owe on current claims, creating unpredictable revenue impairment. This risk is amplified by the episode billing model, where it bears the cost for patients who require more than the estimated number of tests.
About Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.